Phase 1 Safety: Incidence and severity of solicited local reactogenicity AEs;Phase 1 Safety: Incidence and severity of solicited systemic reactogenicity AEs;Phase 1 Safety: Incidence and severity of unsolicited AEs;Phase 1 Safety: Incidence and severity of unsolicited AEs;Phase 1 Safety: Incidence of changes of laboratory safety examinations;Phase 1 Safety: Incidence of MAAEs and SAEs;Phase 1 Safety: Incidence of MAAEs and SAEs;Phase 1 Safety: Vital Sign - Blood Pressure;Phase 1 Safety: Vital Sign - Heart Rate;Phase 1 Safety: Vital Sign - Respiratory Rate;Phase 1 Safety: Vital Sign - Temperature;Phase 2 Efficacy: Percent of subjects that show an increase in N-reactive T cells

Phase 1 Safety: Incidence and severity of solicited local reactogenicity AEs;Phase 1 Safety: Incidence and severity of solicited systemic reactogenicity AEs;Phase 1 Safety: Incidence and severity of unsolicited AEs;Phase 1 Safety: Incidence and severity of unsolicited AEs;Phase 1 Safety: Incidence of changes of laboratory safety examinations;Phase 1 Safety: Incidence of MAAEs and SAEs;Phase 1 Safety: Incidence of MAAEs and SAEs;Phase 1 Safety: Vital Sign - Blood Pressure;Phase 1 Safety: Vital Sign - Heart Rate;Phase 1 Safety: Vital Sign - Respiratory Rate;Phase 1 Safety: Vital Sign - Temperature;Phase 2 Efficacy: Percent of subjects that show an increase in N-reactive T cells